Compare Inovio Pharmaceuticals Inc (INO) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs SYSCO Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while SYSCO Corporation trades at $78.58 (market cap $38.47B). The key difference: SYSCO Corporation is far larger — about 342.9× Inovio Pharmaceuticals Inc's market cap, and SYSCO Corporation pays a 2.81% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and SYSCO Corporation for 77 Days on average.
| INO | SYY | |
|---|---|---|
Market Cap | $112.19M | $38.47B |
Volume | 3,201,278 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $2.65 | $91.16 |
52-Week Low | $0.66 | $69.30 |
Typical Hold Time | 43 Days | 77 Days |
Enterprise Value | $83.51M | $51.65B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Sysco Corporation (SYY) trades at $78.14, up 1.76% with neutral technical signals. The company maintains steady revenue growth reaching $81.37B in 2025, though net margins compressed to 2.08%. Recent corporate actions include a $1.5B senior notes offering and a $0.55 dividend declaration. Technical indicators show mixed signals with RSI neutral at 49.4 and ADX suggesting weak trend direction. The stock trades below analyst consensus target of $85.75 with 60% buy ratings.
Sysco presents a balanced investment case with attractive valuation metrics (P/S 0.44) and strong institutional support, offset by margin pressure and elevated debt levels. The AI efficiency program targeting $500M savings by 2029 provides growth catalyst potential. Key risks include competitive pressures in food distribution and sensitivity to economic cycles affecting restaurant demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
